Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 14.

Wenger, U; Cottini, S R; Noll, G; Arndt, S; Stehberger, P A; Klinzing, S; Schuepbach, R A; Bechir, M (2013). Pretransplant dyslipidaemia determines outcome in lung transplant recipients. Lipids in Health and Disease, 12:53.

Schuepbach, R A. Gerinnungsproteasen als Therapie der Sepsis. 2012, University of Zurich, Faculty of Medicine.

Zinkernagel, A S; Hruz, P; Uchiyama, S; von Köckritz-Blickwede, M; Schuepbach, R A; Hayashi, T; Carson, D A; Nizet, V (2012). Importance of toll-like receptor 9 in host defense against M1T1 Group A Streptococcus infections. Journal of Innate Immunity, 4(2):213-218.

Schuepbach, R A; Madon, J; Ender, M; Galli, P; Riewald, M (2012). Protease-activated receptor-1 cleaved at R46 mediates cytoprotective effects. Journal of Thrombosis and Haemostasis (JTH), 10(8):1675-1684.

Schuepbach, R A; Bestmann, L; Bechir, M; Fehr, J; Bachli, E B (2011). High prevalence of iron deficiency among educated hospital employees in Switzerland. International Journal of Biomedical Science, 7(2):150-157.

Schuepbach, R A; Velez, K; Riewald, M (2011). Activated protein C up-regulates procoagulant tissue factor activity on endothelial cells by shedding the TFPI Kunitz 1 domain. Blood, 117(23):6338-6346.

Quiblier, C; Zinkernagel, A S; Schuepbach, R A; Berger-Bächi, B; Senn, M M (2011). Contribution of SecDF to Staphylococcus aureus resistance and expression of virulence factors. BMC Microbiology, 11:72.

Oberkofler, C E; Stocker, R; Raptis, D A; Stover, J F; Schuepbach, R A; Müllhaupt, B; Dutkowski, P; Clavien, P L; Béchir, M (2010). Same quality - higher price? The paradox of allocation: the first national single center analysis after the implementation of the new Swiss transplantation law: the ICU view. Clinical Transplantation, 25(6):921-928.

Schuepbach, R A; Riewald, M (2010). Coagulation factor Xa cleaves protease-activated receptor-1 and mediates signaling dependent on binding to the endothelial protein C receptor. Journal of Thrombosis and Haemostasis, 8(2):379-388.

Oberkofler, C E; Dutkowski, P; Stocker, R; Schuepbach, R A; Stover, J F; Clavien, P A; Béchir, M (2010). Model of end stage liver disease (MELD) score greater than 23 predicts length of stay in the ICU but not mortality in liver transplant recipients. Critical Care, 14(3):R117.

Bosshart, M; Stover, J F; Stocker, R; Asmis, L M; Feige, J; Neff, T A; Schuepbach, R A; Cottini, S R; Béchir, M (2010). Two different hematocrit detection methods: Different methods, different results? BMC Research Notes, 3:65.

Mosnier, L O; Zampolli, A; Kerschen, E J; Schuepbach, R A; Banerjee, Y; Fernández, J A; Yang, X V; Riewald, M; Weiler, H; Ruggeri, Z M; Griffin, J H (2009). Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood, 113(23):5970-5978.

Schuepbach, R A; Feistritzer, C; Fernández, J A; Griffin, J H; Riewald, M (2009). Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. Thrombosis and Haemostasis, 101(4):724-733.

Bachli, E B; Schuepbach, R A; Maggiorini, M; Stocker, R; Müllhaupt, B; Renner, E L (2007). Artificial liver support with the molecular adsorbent recirculating system: activation of coagulation and bleeding complications. Liver International, 27(4):475-84.

This list was generated on Fri Aug 17 15:07:38 2018 CEST.